Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039572 · ClinicalTrials.gov registry record · Phase 1
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00039572 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center.
The verdict
NCT00039572, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who have glioblastoma multiforme or melanoma metastatic to the brain.
Interventions
- DRUG boronophenylalanine-fructose complex
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-05 |
| Est. Completion | 2005-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039572
The ClinicalTrials.gov registry entry for NCT00039572 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which boronophenylalanine-fructose complex is the first listed.
NCT00039572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039572 about?
NCT00039572 is a clinical study titled "Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain". RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who have glioblastoma multiforme or melanoma metastatic to the brain.
What is the current status of trial NCT00039572?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-05. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00039572?
The interventions under investigation include: boronophenylalanine-fructose complex (DRUG).
Who is sponsoring clinical trial NCT00039572?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.